Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lexaria Bioscience Corp. (LEXX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.34+0.02 (+0.38%)
At close: 1:00PM EST
Advertisement

Lexaria Bioscience Corp.

100 – 740 McCurdy Road
Kelowna, BC V1X 2P7
Canada
250 765 6424
http://www.lexariabioscience.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher A. BunkaChairman & CEO237.48kN/A1962
Mr. John M. DochertyPres & Director191.47kN/A1969
Mr. Gregory John Downey CPA, CMAChief Financial OfficerN/AN/A1961
Vanessa CarleHead of LegalN/AN/AN/A
Dr. Philip AinslieAdvisor & ConsultantN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

Corporate Governance

Lexaria Bioscience Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement